Biomea Fusion Inc to Discuss FDA Clearance of IND for BMF-219 in Type 2 Diabetes Transcript
Good day and thank you for standing by. Welcome to the FDA clearance of IND for BMF-219 in type 2 diabetes conference call.
At this time, all participants are on a listen-only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Ramses Erdtmann, President of Biomea Fusion. Please go ahead.
Thank you, operator. Good afternoon, everyone, and thank you for dialing in. My name is Ramses Erdtmann. I'm the COO, President and Co-Founder of Biomea. With me on the call today from our team and available to answer questions are our CEO and Chairman, Tom Butler, also Co-Founder of Biomea, as well as our CMO, Dr. Steve Morris, our Senior Medical Director, Dr. Sanchita Mourya, and our Associate Director of Translational Research, Dr. Priyanka
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |